检验医学 ›› 2023, Vol. 38 ›› Issue (11): 1009-1014.DOI: 10.3969/j.issn.1673-8640.2023.11.001

• 论著 •    下一篇

基于WES识别中国人群甲状腺乳头状癌新易感基因变异EPB41L4A rs1455421289

闫安1, 关煦慧子1, 蔚田1, 缪刚2, 赵艳阳1()   

  1. 1.北京医院/北京老年医学研究所 国家老年医学中心,北京 100730
    2.北京医院普通外科,北京 100730
  • 收稿日期:2023-04-12 修回日期:2023-09-26 出版日期:2023-11-30 发布日期:2024-01-10
  • 通讯作者: 赵艳阳,E-mail:yanyangzhaobj@gmail.com
  • 作者简介:闫 安,女,1996年生,学士,主要从事肿瘤遗传学病因及机制研究。
  • 基金资助:
    国家自然科学基金项目(81541152);中央高水平医院临床科研项目(BJ-2020-169)

Identification of a new susceptibility gene variant EPB41L4A rs1455421289 in Chinese PTC patients by WES

YAN An1, GUAN Xuhuizi1, YU Tian1, MIAO Gang2, ZHAO Yanyang1()   

  1. 1. Beijing Hospital,Beijing Institute of Geriatrics,National Center of Gerontology,Beijing 100730,China
    2. Department of General Surgery,Beijing Hospital,Beijing 100730,China
  • Received:2023-04-12 Revised:2023-09-26 Online:2023-11-30 Published:2024-01-10

摘要:

目的 采用全外显子组测序(WES)结合靶向分析识别中国人群甲状腺乳头状癌(PTC)新的易感基因变异。方法 选取2018—2020年北京医院行手术治疗的PTC患者286例,用于识别PTC候选基因的变异位点。选取2021—2022年北京医院行手术治疗的PTC患者214例,用于验证变异位点的突变频率。采用WES检测所有研究对象外周血白细胞基因组DNA,并采用靶向分析识别全基因组关联研究(GWAS)定位的28个PTC候选基因的蛋白编码区,及其侧翼选择性剪接序列的罕见变异。检测变异携带者癌组织和癌旁组织中变异位点等位基因的表达情况。通过病例-对照关联分析评估变异位点对PTC发生风险的影响。对照人群的基因分型数据分别来自gnomAD数据库、TOPMed数据库、ChinaMAP数据库和HUABIAO数据库。结果 WES结合靶向分析识别出红细胞膜蛋白4.1样4A(EPB41L4A)基因上的2个极罕见错义突变(rs1455421289位点c.163G>C:p.D55H和rs761977647位点c.855G>C:p.W285C),可能潜在影响编码蛋白的功能。在用于识别PTC候选基因变异位点的286例PTC患者中,有3例携带rs1455421289位点c.163G>C:p.D55H变异,1例携带rs761977647位点c.855G>C:p.W285C变异。这2个位点在4个对照人群中的携带频率均<0.05%。在用于计算变异位点突变频率的214例PTC患者中,有1例携带rs1455421289位点c.163G>C:p.D55H变异,未发现rs761977647位点c.855G>C:p.W285C变异。EPB41L4A rs1455421289的突变频率为0.8%(4/500),rs761977647的突变频率为0.2%(1/500)。EPB41L4A rs1455421289变异导致突变型mRNA的表达丰度显著高于野生型mRNA(P<0.01)。与4个对照人群比较,携带rs1455421289位点c.163G>C:p.D55H变异者PTC发生风险显著升高[比值比(OR)]值分别为40.3、85.4、213.5、541.1,95%可信区间(CI)分别为4.5~361.5、9.5~765.4、57.2~797.2、98.9~2 960.8)。结论 基于WES识别出1个新的PTC易感基因变异EPB41L4A rs1455421289,该变异位点携带者PTC的发生风险显著增高。

关键词: 红细胞膜蛋白带4.1样4A基因, 易感基因, 甲状腺乳头状癌, 全外显子组测序, 中国人群

Abstract:

Objective To identify new susceptibility gene variants in Chinese papillary thyroid carcinoma(PTC) patients by whole exome sequencing(WES) combined with targeted analysis. Methods A total of 286 PTC patients who underwent surgery at Beijing Hospital from 2018 to 2020 were enrolled to identify mutation sites in PTC candidate genes,and 214 PTC patients who underwent surgery at Beijing Hospital from 2021 to 2022 were enrolled to calculate the mutation frequencies of these mutation sites. WES was used to determine peripheral blood leukocyte genomic DNA of all the subjects. Rare variants in protein-coding regions and flanking selective splicing sequences of 28 PTC candidate genes identified by genome-wide association study(GWAS) were identified using targeted analysis. The allele expression of mutation sites in tumor tissues and adjacent tissues was determined. Case-control association analysis was performed to assess the effect of mutation sites on PTC risk. Genotyping data for the controls were obtained from gnomAD,TOPMed,ChinaMAP and HUABIAO databases. Results Two extremely rare missense mutations were identified on the erythrocyte membrane protein band 4.1 like 4A(EPB41L4A) gene(rs1455421289 site c.163G>C:p.D55H and rs761977647 site c.855G>C:p.W285C),which could potentially affect protein function. Among the 286 PTC patients used to identify candidate gene mutation sites,3 patients carried rs1455421289 site c.163G>C:p.D55H mutation,and 1 patient carried the rs761977647 site c.855G>C:p.W285C mutation. The carry frequency of these 2 sites was <0.05% in all 4 control groups. Among the 214 PTC patients used to calculate mutation site mutation frequencies,1 patient carried rs1455421289 site c.163G>C:p.D55H mutation,and no rs761977647 site c.855G>C:p.W285C mutation was determined. The mutation frequency of EPB41L4A rs1455421289 was 0.8%(4/500),and rs761977647 had a mutation frequency of 0.2%(1/500). Moreover,the EPB41L4A rs1455421289 mutation resulted in significantly increased abundance of mutant mRNA compared to wild mRNA(P<0.01). The rs1455421289 site C.163G>C:p.D55H mutation resulted in significantly increased PTC risk compared to the 4 control groups [odds ratios(OR) were 40.3,85.4,213.5 and 541.1,95% confidence intervals(CI) were 4.5-361.5,9.5-765.4,57.2-797.2 and 98.7-2 960.8]. Conclusions Based on WES,a new susceptibility gene variant EPB41L4A rs1455421289 results in significantly increased risk of PTC.

Key words: Erythrocyte membrane protein band 4.1 like 4A, Susceptibility gene, Papillary thyroid carcinoma, Whole exome sequencing, Chinese

中图分类号: